BBT 002
Alternative Names: BBT-002Latest Information Update: 16 Mar 2025
At a glance
- Originator Bambusa Therapeutics
- Class Bispecific antibodies; Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Gastrointestinal disorders; Respiration disorders; Skin disorders
Most Recent Events
- 06 Mar 2025 Preclinical trials in Gastrointestinal disorders in USA (Parenteral), prior to March 2025 (Bambusa therapeutics pipeline, March 2025)
- 06 Mar 2025 Preclinical trials in Respiration disorders in USA (Parenteral), prior to March 2025 (Bambusa therapeutics pipeline, March 2025)
- 06 Mar 2025 Preclinical trials in Skin disorders in USA (Parenteral), prior to March 2025 (Bambusa therapeutics pipeline, March 2025)